Effect of the G375C and G346E achondroplasia mutations on FGFR3 activation

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  He, Lijuan ^a   Serrano, Christopher ^a   Niphadkar, Nitish ^a   Shobnam, Nadia ^a   Hristova, Kalina ^a  

^a Johns Hopkins University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CYSTEINE; DIMER; FIBROBLAST GROWTH FACTOR RECEPTOR 3; GLUTAMIC ACID; GLYCINE; MUTANT PROTEIN;

ACHONDROPLASIA; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; DISEASE SEVERITY; DWARFISM; EMBRYO; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; MUTATIONAL ANALYSIS; PHENOTYPE; PROTEIN CROSS LINKING; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY;

ACHONDROPLASIA; AMINO ACID SUBSTITUTION; FIBROBLAST GROWTH FACTOR 1; GENE EXPRESSION; HEK293 CELLS; HUMANS; LIGANDS; MUTATION; PHOSPHORYLATION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3;

EID: 84859976618     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034808     Document Type: Article

References (47)

1. Blume-Jensen P, Hunter T, (2001) Oncogenic kinase signalling. Nature 411: 355-365.
2. Brunelleschi S, Penengo L, Santoro MM, Gaudino G, (2002) Receptor tyrosine kinases as target for anti-cancer therapy. Current Pharmaceutical Design 8: 1959-1972.
3. van der Geer P, Hunter T, Lindberg RA, (1994) Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol 10: 251-337.
4. Browne BC, O'Brien N, Duffy MJ, Crown J, O'Donovan N, (2009) HER-2 Signaling and Inhibition in Breast Cancer. Current Cancer Drug Targets 9: 419-438.
5. Hubbard SR, Miller WT, (2007) Receptor tyrosine kinases: mechanisms of activation and signaling. Cur Opinion Cell Biol 19: 117-123.
6. Schlessinger J, (2000) Cell signaling by receptor tyrosine kinases. Cell 103: 211-225.
7. Mohammadi M, Dikic I, Sorokin A, Burgess WH, Jaye M, et al. (1996) Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction. Mol Cell Biol 16: 977-989.
8. Fantl WJ, Johnson DE, Williams LT, (1993) Signaling by Receptor Tyrosine Kinases. Annu Rev Biochem 62: 453-481.
9. Plotnikov AN, Schlessinger J, Hubbard SR, Mohammadi M, (1999) Structural basis for FGF receptor dimerization and activation. Cell 98: 641-650.
10. Harada D, Yamanaka Y, Ueda K, Tanaka H, Seino Y, (2009) FGFR3-related dwarfism and cell signaling. Journal of Bone and Mineral Metabolism 27: 9-15.
11. Vajo Z, Francomano CA, Wilkin DJ, (2000) The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: The achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans. Endocrine Reviews 21: 23-39.
12. Webster MK, Donoghue DJ, (1997) FGFR activation in skeletal disorders: Too much of a good thing. Trends Genet 13: 178-182.
13. Robertson SC, Tynan JA, Donoghue DJ, (2000) RTK mutations and human syndromes- when good receptors turn bad. Trends Genet 16: 265-271.
14. Choi SH, Mendrola JM, Lemmon MA, (2007) EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer. Oncogene 26: 1567-1576.
15. Ibrahimi OA, Zhang FM, Eliseenkova AV, Linhardt RJ, Mohammadi M, (2004) Proline to arginine mutations in FGF receptors 1 and 3 result in Pfeiffer and Muenke craniosynostosis syndromes through enhancement of FGF binding affinity. Human Molecular Genetics 13: 69-78.
16. Li E, Hristova K, (2006) Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies. Biochemistry 45: 6241-6251.
17. He L, Hristova K, (2008) Pathogenic activation of receptor tyrosine kinases in mammalian membranes. J Mol Biol 384: 1130-1142.
18. Han X, Mihailescu M, Hristova K, (2006) Neutron diffraction studies of fluid bilayers with transmembrane proteins: Structural consequences of the achondroplasia mutation. Biophys J 91: 3736-3747.
19. Adar R, Monsonego-Ornan E, David P, Yayon A, (2002) Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization. Journal of Bone and Mineral Research 17: 860-868.
20. Casteran N, De Sepulveda P, Beslu N, Aoubala M, Letard S, et al. (2003) Signal transduction by several KIT juxtamembrane domain mutations. Oncogene 22: 4710-4722.
21. Weiner DB, Liu J, Cohen JA, Williams WV, Greene MI, (1989) A Point Mutation in the Neu Oncogene Mimics Ligand Induction of Receptor Aggregation. Nature 339: 230-231.
22. Passos-Bueno MR, Wilcox WR, Jabs EW, Sertié AL, Alonso LG, et al. (1999) Clinical spectrum of fibroblast growth factor receptor mutations. Human Mutation 14: 115-125.
23. Naski MC, Wang Q, Xu JS, Ornitz DM, (1996) Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat Genet 13: 233-237.
24. Cohen MM, (2006) The new bone biology: Pathologic, molecular, and clinical correlates. American Journal of Medical Genetics Part A 140A: 2646-2706.
25. Cohen MM, (2002) Some chondrodysplasias with short limbs: Molecular perspectives. American Journal of Medical Genetics 112: 304-313.
26. Cohen MM, (1997) Short-limb skeletal dysplasias and craniosynostosis: What do they have in common? Pediatric Radiology 27: 442-446.
27. Cohen MM, (1998) Achondroplasia, hypochondroplasia and thanatophoric dysplasia: clinically related skeletal dysplasias that are also related at the molecular level. International Journal of Oral and Maxillofacial Surgery 27: 451-455.
28. Rump P, Letteboer TGW, Gille JJP, Torringa MJL, Baerts W, et al. (2006) Severe complications in a child with achondroplasia and two FGFR3 mutations on the same allele. American Journal of Medical Genetics Part A 140A: 284-290.
29. Park WJ, Bellus GA, Jabs EW, (1995) Mutations in Fibroblast Growth-Factor Receptors- Phenotypic Consequences During Eukaryotic Development. American Journal of Human Genetics 57: 748-754.
30. Prinos P, Kilpatrick MW, Tsipouras P, (1995) A novel G346E FGFR3 mutation in achondroplasia. Pediatr Res Suppl 37: 151A.
31. Chen F, Degnin C, Laederich MB, Horton AW, Hristova K, (2011) The A391E mutation enhances FGFR3 activation in the absence of ligand. Biochimica et Biophysica Acta-Biomembranes 1808: 2045-2050.
32. Chen FH, Hristova K, (2011) The Physical Basis of FGFR3 Response to fgf1 and fgf2. Biochemistry 50: 8576-8582.
33. He L, Wimley WC, Hristova K, (2011) FGFR3 heterodimerization in achondroplasia, the most common form of human dwarfism. J Biol Chem 286: 13272-13281.
34. He LJ, Shobnam N, Hristova K, (2011) Specific inhibition of a pathogenic receptor tyrosine kinase by its transmembrane domain. Biochimica et Biophysica Acta-Biomembranes 1808: 253-259.
35. He L, Horton WA, Hristova K, (2010) The physical basis behind achondroplasia, the most common form of human dwarfism. J Biol Chem 285: 30103-30114.
36. Ponseti IV, (1970) Skeletal Growth in Achondroplasia. Journal of Bone and Joint Surgery-American Volume A 52: 701-3.
37. Horton WA, Hall JG, Hecht JT, (2007) Achondroplasia. Lancet 370: 162-172.
38. Shiang R, Thompson LM, Zhu Y-Z, Church DM, Fielder TJ, et al. (1994) Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 78: 335-342.
39. Webster MK, Donoghue DJ, (1996) Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. EMBO J 15: 520-527.
40. Li E, You M, Hristova K, (2006) FGFR3 dimer stabilization due to a single amino acid pathogenic mutation. J Mol Biol 356: 600-612.
41. You M, Spangler J, Li E, Han X, Ghosh P, et al. (2007) Effect of pathogenic cysteine mutations on FGFR3 transmembrane domain dimerization in detergents and lipid bilayers. Biochemistry 46: 11039-11046.
42. Cho JY, Guo CS, Torello M, Lunstrum GP, Iwata T, et al. (2004) Defective lysosomal targeting of activated fibroblast growth factor receptor 3 in achondroplasia. Proceedings of the National Academy of Sciences of the United States of America 101: 609-614.
43. Monsonego-Ornan E, Adar R, Rom E, Yayon A, (2002) FGF receptors ubiquitylation: dependence on tyrosine kinase activity and role in downregulation. FEBS Lett 528: 83-89.
44. Bonaventure J, Gibbs L, Horne WC, Baron R, (2007) The localization of FGFR3 mutations causing thanatophoric dysplasia type I differentially affects phosphorylation, processing and ubiquitylation of the receptor. Febs Journal 274: 3078-3093.
45. Monsonego-Ornan E, Adar R, Feferman T, Segev O, Yayon A, (2000) The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation. Mol Cell Biol 20: 516-522.
46. Bellus GA, Spector EB, Speiser PW, Weaver CA, Garber AT, et al. (2000) Distinct missense mutations of the FCFR3 Lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype. American Journal of Human Genetics 67: 1411-1421.
47. Meyers GA, Orlow SJ, Munro IR, Przylepa KA, Jabs EW, (1995) Fibroblast-Growth-Factor-Receptor-3 (Fgfr3) Transmembrane Mutation in Crouzon-Syndrome with Acanthosis Nigricans. Nat Genet 11: 462-464.